In a recent large metaanalysis of patients receiving nonsteroidal anti-inflammatory drugs (NSAID), including COX-2 selective COXibs, NSAID use was associated with reduced risk for breast cancer (relative risk [RR] = 0.88, 95% confidence interval [95% CI] = 0.84 to 0.93) [4]. Here, PTGS2 is linked to breast cancer.